BC Extra | Dec 9, 2019
Company News

With $2.7B ArQule buyout, Merck is latest pharma to jump into Btk race

With its proposed acquisition of ArQule, Merck will join the ranks of at least three other pharmas adding Btk inhibitors to their portfolios while appearing to pay much less than its peers. The $2.7 billion...
BC Extra | Oct 24, 2019
Preclinical News

Oct. 24 Preclinical Quick Takes: anti-neuraminidase human antibodies for broad flu protection; plus Ionis-Baylor, Merck and more

Broad influenza protection by human antibodies against neuraminidase  A Science study from Scripps Research Institute, Icahn School of Medicine at Mount Sinai and Washington University in St. Louis identified three human antibodies that could serve...
BC Innovations | Jul 26, 2019
Translation in Brief

GI infection as Parkinson’s trigger

A Canadian team has shown how bacterial GI infections can trigger Parkinson's disease in genetically susceptible individuals. The findings add to mounting evidence implicating the gut microbiome in CNS disorders including autism, Alzheimer's disease and...
BC Innovations | Apr 22, 2019
Distillery Therapeutics

The former diabetes drug phenformin for T cell ALL

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL) Cell culture and mouse studies suggest phenformin could help treat PTEN-deficient T cell ALL. In three mouse PTEN-deficient T cell ALL cell lines, phenformin inhibited growth with...
BC Innovations | Jan 4, 2019
Tools & Techniques

Making AD mice as diverse as patients

The Jackson Laboratory aims to make Alzheimer’s disease mouse models more useful for predicting which patients will respond to therapy by engineering in a high degree of genetic diversity to better reflect trial populations. The...
BC Innovations | Dec 11, 2018
Distillery Therapeutics


INDICATION: Prostate cancer Cell culture, patient sample and mouse studies suggest inhibiting SMARCA4 could help treat PTEN-deficient prostate cancer. Screening of a CRISPR single-guide RNA (sgRNA) library targeting 517 genes encoding epigenetic regulators in PTEN-deficient...
BC Innovations | Oct 31, 2018
Distillery Therapeutics


INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting KDM4B alone or in combination with PI3K could help treat PTEN-deficient triple-negative breast cancer (TNBC). In a PTEN-deficient TNBC cell line, two siRNAs against KDM4B...
BC Innovations | Jun 21, 2018
Translation in Brief

PHIP the script

Cancers lacking key molecular signatures targeted by precision therapies are among the most challenging to treat, but a new study has identified a target, PHIP, for three of those difficult tumor types. A group led...
BC Extra | May 2, 2018
Preclinical News

UCSF study suggests stress response inhibitor could treat prostate cancer

A new study from University of California San Francisco researchers suggests that releasing the "brakes" on a tumor's stress regulation system by inhibiting eukaryotic translation initiation factor 2A (EIF2A) could help treat metastatic prostate cancer....
BC Innovations | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
Items per page:
1 - 10 of 172